These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23214487)
1. [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension]. Karhanová M; Mlčák P; Fryšák Z; Marešová K Cesk Slov Oftalmol; 2012 Oct; 68(4):150-5. PubMed ID: 23214487 [TBL] [Abstract][Full Text] [Related]
2. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Hommer A; Mohammed Ramez O; Burchert M; Kimmich F Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122 [TBL] [Abstract][Full Text] [Related]
3. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Erb C; Lanzl I; Seidova SF; Kimmich F Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844 [TBL] [Abstract][Full Text] [Related]
4. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237 [TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086 [TBL] [Abstract][Full Text] [Related]
6. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence. Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035 [TBL] [Abstract][Full Text] [Related]
7. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. Traverso CE; Ropo A; Papadia M; Uusitalo H J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients. Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE Expert Opin Drug Saf; 2012 Jul; 11(4):519-25. PubMed ID: 22690824 [TBL] [Abstract][Full Text] [Related]
9. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371 [TBL] [Abstract][Full Text] [Related]
10. Spanish multicenter tafluprost tolerability study. Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693 [TBL] [Abstract][Full Text] [Related]
11. Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Uusitalo H; Pillunat LE; Ropo A; Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586 [TBL] [Abstract][Full Text] [Related]
13. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension. Swymer C; Neville MW Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study. Lee W; Lee S; Bae H; Kim CY; Seong GJ BMC Ophthalmol; 2017 Apr; 17(1):61. PubMed ID: 28454526 [TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. Holló G; Katsanos A Expert Opin Drug Saf; 2015 Apr; 14(4):609-17. PubMed ID: 25640746 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C; Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707 [TBL] [Abstract][Full Text] [Related]
18. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Olander K; Zimmerman TJ; Downes N; Schoenfelder J; Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478 [TBL] [Abstract][Full Text] [Related]
19. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Kuwayama Y; Nomura A Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289 [TBL] [Abstract][Full Text] [Related]
20. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma. Konstas AG; Holló G Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]